Hematopoietin functions as a longevity promoter: Erythropoietin (EPO)/Hematopoietin, a glycoprotein cytokine that promotes erythropoiesis, may increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes, 12/Decemeber/2018, 6.35 am
A probiotic way to stay free of autoimmune diabetes: Probiotic VSL#C increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 12/December/2018, 6.19 am
December 12, 2018
XBP1-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: XBP1, a regulator of the immune system, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 12/December/2018, 6.47 am
December 12, 2018
What they say: Introduction:
A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston, USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July 2014 issue of the journal “EMBO”, by Prof Sinclair, North BJ, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Hematopoietin functions as a longevity promoter: Erythropoietin (EPO)/Hematopoietin, a glycoprotein cytokine that promotes erythropoiesis, may increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes
From research findings to Therapeutic Opportunity:
This study suggests, for the first time, that Erythropoietin (EPO), by increasing the expression of its target gene, may: (a) increase the expression of BuBR1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase); (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (fig. 1).
Figure 1. Erythropoietin (EPO)/Hematopoietin functions as a longevity promoter. Astragalus polysaccharide may extend mammalian lifespan via up-regulation of BuBR1; and down-regulation of p70 S6 Kinase
Figure 2. Erythropoietin (EPO)/Hematopoietin functions as a longevity-promoter through induction of BuBR1.
Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median lifespan. Thus, Erythropoietin (EPO) or its activators, either alone or in combination with other drugs,“ may be used to extend the lifespan of an individual (fig.2).
[easy_payment currency=”USD”]
Details on the research findings:
Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.
Amount: $75
0#
Undisclosed mechanistic information: How Erythropoietin (EPO) increases the expression of BubR1 and extend mammalian life-span
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
# Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Hematopoietin functions as a longevity promoter: Erythropoietin (EPO)/Hematopoietin, a glycoprotein cytokine that promotes erythropoiesis, may increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes, 12/Decemeber/2018, 6.35 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at admin@genomediscovery.org
